Wellington Management Group LLP Karuna Therapeutics, Inc. Transaction History

Wellington Management Group LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$161.01 - $317.85 $183 Million - $360 Million	1,134,046 New	1,134,046 $359 Million
Q3 2023 Nov 14, 2023	SELL	$164.66 - $218.08 $18.9 Million - $25 Million	-114,729 Reduced 8.19%	1,285,508 $217 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $36.4 Million - $49.6 Million	-206,617 Reduced 12.86%	1,400,237 $304 Million
Q1 2023 May 12, 2023	BUY	$161.33 - $204.36 $89 Million - $113 Million	551,778 Added 52.3%	1,606,854 $292 Million
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $10.3 Million - $12.8 Million	53,973 Added 5.39%	1,055,076 $207 Million

Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $7.79 Million - $17.5 Million	62,954 Added 6.71%	1,001,103 $225 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $7.97 Million - $12.2 Million	84,812 Added 9.94%	938,149 $119 Million
Q1 2022 May 16, 2022	SELL	$98.9 - $132.37 $14 Million - $18.7 Million	-141,202 Reduced 14.2%	853,337 $108 Million
Q4 2021 Feb 11, 2022	SELL	$110.64 - $159.4 $812,872 - $1.17 Million	-7,347 Reduced 0.73%	994,539 $130 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $5.6 Million - $6.96 Million	55,305 Added 5.84%	1,001,886 $123 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $31.1 Million - $39.4 Million	289,685 Added 44.1%	946,581 $108 Million
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $50 Million - $69.7 Million	523,865 Added 393.79%	656,896 $79 Million
Q4 2020 Feb 12, 2021	BUY	$75.23 - $109.23 $10 Million - $14.5 Million	133,031 New	133,031 $13.5 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.